Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1962 1
1963 2
1964 1
1965 2
1966 3
1967 1
1969 1
1975 1
1978 1
1981 2
1982 2
1983 4
1984 5
1985 3
1986 2
1987 2
1988 3
1989 4
1990 4
1991 1
1993 2
1994 1
1995 1
1996 1
1997 4
1998 1
1999 13
2000 1
2001 3
2002 6
2004 5
2005 3
2006 3
2007 12
2008 15
2009 6
2010 6
2011 5
2012 9
2013 9
2014 7
2015 11
2016 9
2017 5
2018 4
2019 8
2020 14
2021 15
2022 15
2023 7
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

227 results

Results by year

Filters applied: . Clear all
Page 1
Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19.
Levin MJ, Ustianowski A, De Wit S, Launay O, Avila M, Templeton A, Yuan Y, Seegobin S, Ellery A, Levinson DJ, Ambery P, Arends RH, Beavon R, Dey K, Garbes P, Kelly EJ, Koh GCKW, Near KA, Padilla KW, Psachoulia K, Sharbaugh A, Streicher K, Pangalos MN, Esser MT; PROVENT Study Group. Levin MJ, et al. N Engl J Med. 2022 Jun 9;386(23):2188-2200. doi: 10.1056/NEJMoa2116620. Epub 2022 Apr 20. N Engl J Med. 2022. PMID: 35443106 Free PMC article. Clinical Trial.
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.
Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ, Carles J, Flaig TW, Taplin ME, Higano CS, de Souza P, de Bono JS, Griffin TW, De Porre P, Yu MK, Park YC, Li J, Kheoh T, Naini V, Molina A, Rathkopf DE; COU-AA-302 Investigators. Ryan CJ, et al. Lancet Oncol. 2015 Feb;16(2):152-60. doi: 10.1016/S1470-2045(14)71205-7. Epub 2015 Jan 16. Lancet Oncol. 2015. PMID: 25601341 Clinical Trial.
AUTHOR REPLY.
Townsend WB, Worrilow WM, Riggs SB. Townsend WB, et al. Among authors: riggs sb. Urology. 2020 Sep;143:193. doi: 10.1016/j.urology.2020.04.118. Urology. 2020. PMID: 32862947 Free PMC article. No abstract available.
Abiraterone and increased survival in metastatic prostate cancer.
de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Fléchon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI; COU-AA-301 Investigators. de Bono JS, et al. N Engl J Med. 2011 May 26;364(21):1995-2005. doi: 10.1056/NEJMoa1014618. N Engl J Med. 2011. PMID: 21612468 Free PMC article. Clinical Trial.
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE; COU-AA-302 Investigators. Ryan CJ, et al. N Engl J Med. 2013 Jan 10;368(2):138-48. doi: 10.1056/NEJMoa1209096. Epub 2012 Dec 10. N Engl J Med. 2013. PMID: 23228172 Free PMC article. Clinical Trial.
Reply by Authors.
Roebuck E, Urquieta de Hernandez B, Wheeler M, Stearns G, Patel M, Guice S, Roy OP, Clark PE, Riggs SB. Roebuck E, et al. Among authors: riggs sb. Urol Pract. 2022 Jan;9(1):93. doi: 10.1097/UPJ.0000000000000273.02. Epub 2021 Oct 11. Urol Pract. 2022. PMID: 37145587 No abstract available.
Reply by Authors.
Johny A, Shenot PJ, Green C, Chisholm L, Riggs S, Jackman SV, Khan AA, Kolettis PN, McNeil BK, Mayer WA. Johny A, et al. Among authors: riggs s. Urol Pract. 2024 May;11(3):586. doi: 10.1097/UPJ.0000000000000563. Epub 2024 Mar 20. Urol Pract. 2024. PMID: 38560965 No abstract available.
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study.
Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, Staffurth JN, North S, Vogelzang NJ, Saad F, Mainwaring P, Harland S, Goodman OB Jr, Sternberg CN, Li JH, Kheoh T, Haqq CM, de Bono JS; COU-AA-301 Investigators. Fizazi K, et al. Lancet Oncol. 2012 Oct;13(10):983-92. doi: 10.1016/S1470-2045(12)70379-0. Epub 2012 Sep 18. Lancet Oncol. 2012. PMID: 22995653 Clinical Trial.
Bladder sparing, is it underutilized?
Riggs S. Riggs S. Urol Oncol. 2016 Jun;34(6):260-1. doi: 10.1016/j.urolonc.2016.03.007. Epub 2016 May 4. Urol Oncol. 2016. PMID: 27156632 No abstract available.
227 results